Print Page  Close Window

Investor Relations

Corporate Profile
Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. Using breakthrough piezo-print technology for high-precision micro-dosing and the first smart electronic mobile health compliance tracking platform for topical pharmaceuticals, Eyenovia is building a premier eye care company of the future. The company is advancing its two lead assets for glaucoma and mydriasis into Phase III clinical programs and preparing registration studies for a third OTC product for dry eye. Eyenovia is expected to complete all three development programs through registration by 2020. Eyenovia is building a portfolio of superior micro-therapeutics with its proprietary piezo-formulations of existing and new molecular entities.

Price
$8.60

Change
0.00 (0.00%)

Volume
43

Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News Releases
04/19/18
Eyenovia Announces Conference Call and Webcast for First Quarter 2018 Financial Results
Read More
04/02/18
Eyenovia Announces Fourth Quarter and Full Year 2017 Financial Results
Read More
03/26/18
Eyenovia Appoints Three Industry Veterans to Board of Directors
Read More
Upcoming Events
DateTitle
05/09/18 8:30 a.m. ET
Eyenovia Inc. First Quarter 2018 Earnings Call